Wells Fargo raised its price target on Fate Therapeutics (NASDAQ: FATE) to $18.00 (from $12.00) while maintaining a Outperform rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

H.C. Wainwright Downgrades Fate Therapeutics (FATE) to NeutralMarch 6, 2018 7:57 AM Fate Therapeutics (FATE) PT Raised to $19 at WedbushMarch 6, 2018 6:40 AM Fate Therapeutics (FATE) PT Raised to $16 at Leerink Partners; 'IPSC Platform Key Value Driver'March 6, 2018 5:27 AM Fate Therapeutics (FATE) PT Raised to $20 at Piper JaffrayMarch 6, 2018 3:31 AM Fate Therapeutics (FATE) PT Raised to $20 at BMO Capital; 'Enthusiasm for Cell Therapies Probably Justified'March 6, 2018 1:13 AM